A Population-based Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP)
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- West China Hospital
- Enrollment
- 564,760
- Locations
- 1
- Primary Endpoint
- congenital malformations
Study Overview
Brief Summary
The DEEP cohort is the first population-based cohort of pregnant population in China that longitudinally documents drug uses throughout the pregnancy life course and adverse pregnancy outcomes.
Detailed Description
The DEEP cohort is the first population-based cohort of pregnant population in China that longitudinally documents drug uses throughout the pregnancy life course and adverse pregnancy outcomes. The main goal of the study aims to monitor and evaluate the safety of drug use through the pregnancy life course in the Chinese setting. The DEEP cohort is developed primarily based on the population-based data platforms in Xiamen, a municipal city of 5 million population in southeast China. Based on these data platforms, a pregnancy-centered registry was developed that documented health care services and outcomes in the maternal and other departments. For identifying drug uses, a drug prescription database was specifically developed by using electronic healthcare records documented in the platforms across the primary, secondary and tertiary hospitals. By linking the pregnancy registry and prescription database through a unique identifier, the DEEP cohort was developed. All the pregnant women and their offspring in Xiamen are provided with health care and followed up according to standard protocols in the region, including antenatal care, delivery care, postpartum follow-up and childhood follow-ups. The primary adverse outcomes - congenital malformations - are collected using a standardized Case Report Form.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 14 Years to 65 Years (Child, Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Pregnant women who registered at the Maternal and Child Health Management Platform in Xiamen.
Exclusion Criteria
- Not provided
Arms & Interventions
drug exposure
chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs
Intervention: chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs (Drug)
Outcomes
Primary Outcomes
congenital malformations
Time Frame: up to 42 days after delivery
Number of births with congenital malformations
Secondary Outcomes
- preterm birth(up to 37 gestational weeks)
- low birth weight(Immediately after delivery)
Investigators
Sun Xin
Director of Chinese Evidence-based Medicine Center
West China Hospital
